Evaluation of Cinchonidine as a Dual Antioxidant and Acetylcholinesterase Modulator for the Amelioration of AlCl3-Induced Neurotoxicity against Alzheimer's Disease
BackgroundAlzheimer’s disease (AD) is a global health crisis marked by amyloid plaques, tau hyperphosphorylation, and oxidative stress. Cinchonidine, a quinoline alkaloid, is promising herbal medicine with therapeutic benefits as a natural alternative to conventional drugs. This study investigated the neuroprotective potential of Cinchonidine (CD), a cinchona alkaloid and stereoisomer of quinine, using in-silico, in-vitro antioxidant and by in-vivo activity against aluminium chloride-induced cognitive dysfunction in rats.MethodologyMolecular docking of cinchonidine and standard drugs (donepezil) targeting Alzheimer's disease-related proteins (Acetylcholinesterase, PDB: 6ZWE) was performed using AutoDock Vina. Proteins were prepared by removing water and ligands, with active sites predicted via GRID box blind docking. Ligands were sourced from PubChem and converted to PDB format. Docking results were analyzed for binding affinity and interactions using Discovery Studio. In-vitro antioxidant activity of cinchonidine was assessed through H2O2 scavenging, DPPH, and FRAP assays. In-vivo studies employed adult male Wistar rats (200–250 g), divided into six groups (control, AlCl3-induced Alzheimer’s model, three cinchonidine dose groups at 10, 20, and 40 mg/kg, and a donepezil standard group). Treatments were administered orally for 21 days. Cognitive and behavioural assessments included the Elevated Plus Maze, T-maze, Y-maze, and locomotor activity via actophotometer. Post-treatment, hippocampus and cortex homogenates were analysed for acetylcholinesterase activity (Ellman’s method), catalase, lipid peroxidation (MDA via TBARS), and superoxide dismutase activities using spectrophotometric assays.ResultsMolecular docking revealed that cinchonidine binds acetylcholinesterase (AChE) with a −8.3 kcal/mol affinity, forming key hydrogen bonds and hydrophobic interactions, albeit weaker than donepezil (−11.3 kcal/mol). In-vitro assays demonstrated cinchonidine’s dose-dependent antioxidant activity comparable to ascorbic acid across H₂O₂ scavenging, DPPH, and FRAP assays. In-vivo, cinchonidine dose-dependently ameliorated AlCl₃-induced cognitive deficits, anxiety-like behaviour, and locomotor impairments in rats, paralleling donepezil effects. Biochemically, cinchonidine significantly restored brain AChE, lipid peroxidation, catalase, superoxide dismutase, and reduced glutathione levels (p < 0.05-0.001), indicating neuroprotective antioxidant and cholinergic modulation relevant to Alzheimer’s therapy.ConclusionCinchonidine demonstrated significant neuroprotective effects against AlCl3-induced cognitive dysfunction in rats through acetylcholinesterase inhibition and potent antioxidant activity. In-silico, in-vitro, and in-vivo results consistently showed dose-dependent improvements in cognitive behaviour, cholinergic function, and oxidative stress markers, comparable to donepezil. These findings highlight cinchonidine’s potential as a multifunctional therapeutic candidate for Alzheimer’s disease. Further studies exploring molecular mechanisms, long-term safety, and pharmacokinetics are warranted to advance its clinical translation.